Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Reduce" from Brokerages

Key Points

• Analysts hold a consensus “Reduce” rating on Fulcrum Therapeutics, with four sell ratings, seven holds and one buy. The average 12-month price target is $8.20, though recent target updates included $3.00 and $4.00 levels.
• FULC shares opened at $3.74, near their 52-week low of $2.83 and well below the 52-week high of $15.74. The stock’s 200-day moving average was $5.18.
• Fulcrum reported a quarterly loss of $0.34 per share, missing the $0.24 consensus loss estimate, while institutional investors and hedge funds collectively own about 89.83% of the company.

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the twelve research firms that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $8.20.

A number of equities analysts recently issued reports on FULC shares. Stifel Nicolaus downgraded Fulcrum Therapeutics from a "buy" rating to a "hold" rating and set a $3.00 price target for the company. in a report on Tuesday, June 2nd. JPMorgan Chase & Co. downgraded shares of Fulcrum Therapeutics from an "overweight" rating to an "underweight" rating in a research report on Wednesday, June 3rd. Truist Financial cut shares of Fulcrum Therapeutics from a "buy" rating to a "hold" rating and set a $4.00 target price for the company. in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th. Finally, Jefferies Financial Group set a $4.00 price target on shares of Fulcrum Therapeutics in a research note on Tuesday, June 2nd.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ FULC opened at $3.74 on Friday. The company has a market capitalization of $285.36 million, a price-to-earnings ratio of -3.09 and a beta of 2.59. The business has a 50-day moving average of $3.79 and a two-hundred day moving average of $5.18. Fulcrum Therapeutics has a 1 year low of $2.83 and a 1 year high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). As a group, equities research analysts expect that Fulcrum Therapeutics will post -0.6 earnings per share for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in shares of Fulcrum Therapeutics in the 2nd quarter valued at $32,297,000. Nantahala Capital Management LLC acquired a new stake in shares of Fulcrum Therapeutics in the 2nd quarter worth $20,038,646. Siren L.L.C. boosted its holdings in Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company's stock valued at $18,024,000 after purchasing an additional 400,000 shares in the last quarter. First Turn Management LLC acquired a new position in Fulcrum Therapeutics during the 4th quarter worth approximately $21,406,000. Finally, ADAR1 Capital Management LLC acquired a new position in Fulcrum Therapeutics during the 2nd quarter worth approximately $5,728,000. Hedge funds and other institutional investors own 89.83% of the company's stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases that affect skeletal muscle and other tissues. The company uses its FulcrumSeek drug-discovery platform to identify molecular targets and potential therapies for conditions in which the underlying biology is well characterized but treatment options remain limited.

Fulcrum's lead product candidate is losmapimod, an investigational oral therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle-wasting disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.